VivoSeq
Musculoskeletal

Dupuytren's Disease

0

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Dupuytren's Disease is an early-stage landscape with 0 programs across 1 company. The most active players are Endo Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Endo Pharmaceuticals logo

Endo Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

11

clinical trials

Completed7 · 64%
Unknown status2 · 18%
Withdrawn1 · 9%
Active, not recruiting1 · 9%

Clinical Trials

Trial Activity

11 trials

Skin Involvement in Dupuytren Surgical Treatment Outcome: Interventional Study on Prognostic Value of Cutometry, Ultrasound and Histopathology
Active, not recruiting·UUniversitaire Ziekenhuizen KU Leuven·Preclinical·NCT07470684·50 enrolled
Phase III Randomized Study of Collagenase in Patients With Residual Stage Dupuytren's Disease
Completed·SState University of New York·Phase 3·NCT00014742·72 enrolled
Phase II Randomized Study of Collagenase in Patients With Residual Type Dupuytren's Disease
Completed·SState University of New York·Phase 2·NCT00004409·36 enrolled
Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules
Completed·Endo Pharmaceuticals logoEndo Pharmaceuticals·Phase 2·NCT02193828·76 enrolled
Repurposing Anti-TNF for Treating Dupuytren's Disease
Completed·UUniversity of Oxford·Phase 2·NCT03180957·140 enrolled
Non-US Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease
Completed·Endo Pharmaceuticals logoEndo Pharmaceuticals·Phase 3·NCT00533273·66 enrolled
Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease
Completed·Endo Pharmaceuticals logoEndo Pharmaceuticals·Phase 3·NCT00528840·201 enrolled
AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease
Completed·Endo Pharmaceuticals logoEndo Pharmaceuticals·Phase 3·NCT00528424·286 enrolled
Collagenase and Needle Aponeurotomy: Single Modality Versus Combination Treatment for Dupuytren's Disease
Withdrawn·UUniversity of Alberta·Phase 3·NCT01776892
Short-term Function and Pain After Treatment for Dupuytren's Disease
Unknown status·SSunnybrook Health Sciences Centre·N/A·NCT02301078·60 enrolled
Collagenase Injection vs Percutaneous Needle Aponeurotomy for Dupuytren's Disease
Unknown status·UUniversity of Calgary·Phase 4·NCT03000114·334 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)